Home / Oligonucleotides and Peptides / Discovery / Peptide / Stage-Focused Solutions

Stage-Focused Development Solutions

The right support at each stage, so you can move fast and move forward.

Dynamic Support for Evolving Needs

Drug programs don’t move in straight lines. As peptide and oligonucleotide candidates advance, requirements shift — from speed and flexibility in early discovery to robustness, compliance, and scalability in later stages.

WuXi TIDES delivers stage-focused solutions designed to support each phase of development. Our integrated CRDMO model helps programs move forward without disruption as requirements evolve.

Early Discovery & Lead Optimization

At the earliest stages, the goal is insight. WuXi TIDES supports discovery programs with flexible solutions that enable rapid iteration across peptides, oligonucleotides, and conjugates, helping teams evaluate emerging designs efficiently while keeping downstream development in mind.

How this supports your program:

Fast, flexible execution to support screening and optimization
Broad chemistry and modifications available across modalities
Early technical input that informs future development pathways
In-house supply of custom amidites and unnatural amino acids to support rapid design iteration and early evaluation of non-standard modifications

Explore More

Preclinical & IND-Enabling Development

Preclinical and IND-enabling development are distinct regulatory stages, but in practice they often run in parallel once a PCC is confirmed. This is where many early-phase programs slow down, as execution becomes fragmented. API, formulation, analytical, and regulatory activities frequently proceed sequentially or across multiple partners, introducing uncertainty and delays.

At WuXi TIDES, IND-enabling work begins as soon as PCC is confirmed, with aligned teams and a defined CMC plan that connects early development directly to IND requirements. With this approach, IND-ready CMC packages can be achieved in as little as 9 months.

How this supports your program:

Smoother transition from discovery routes to scalable processes
Early CMC thinking to reduce downstream rework
Coordinated support across drug substance, drug product, analytical, and CMC dossier preparation

CMC Development

Clinical Development

Clinical development is where CMC decisions are tested at scale. Processes must deliver consistent quality, analytical methods must withstand regulatory scrutiny, and manufacturing approaches must scale without introducing new risks.

At this stage, success depends on whether development platforms are truly fit for purpose. For example, WuXi TIDES applies optimized technology platform for advanced oligonucleotide modalities — including ASO, siRNA, sgRNA, and PMO — to improve yield, purity, and process robustness as programs move through the clinic. By applying late-phase discipline early, clinical manufacturing remains predictable even as complexity increases, reducing the need for process rework between phases.

How this supports your program:

Consistent technical oversight across clinical phases

Integrated handling of complex and hybrid modalities

Stable processes that scale with clinical needs

Clinical Supply

Commercial Manufacturing

WuXi TIDES’ commercial readiness is built on experience transferring clinical processes into stable, long-term manufacturing platforms. This includes mature control strategies, validated analytics, and supply approaches designed to support continuous production rather than one-time campaigns. As products enter commercialization, this foundation allows changes to be managed deliberately — without disrupting supply or re-opening core process assumptions.